Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 May 2025 | Story Lilitha Dingwayo | Photo Lunga Luthuli
Mock Interview
UFS students shine with confidence at the 2025 Mock Interview Day, ready for career success.

To get senior and postgraduate students ready for the world of work, the University of the Free State (UFS) Division of Career Services’ Placement Preparation Day, which was initiated in 2023, has grown into an annual workshop – Mock Interview Day – with this year’s event taking place in the Callie Human Centre on the Bloemfontein Campus.   

Held on 14 and 15 May 2025, this UFS initiative – aimed at addressing employability – has evolved through the implementation of several educational subdivisions tasked with the responsibility of assisting all registered students understand the professional environment. One of these divisions is the Centre for Teaching and Learning’s (CTL) ‘Graduate Attributes’ – an initiative that seeks to assess a student’s development of valuable attributes during lectures.

According to Belinda Janeke, Assistant Director of Career Services, “Feedback indicates that most students have no interview experience – a critical factor. It is through these mock interviews that students’ confidence is built and their transition from student to employee is smoothened.” 

With the assistance of staff members and employees in conducting the interviews, the two-day initiative has seen evident success in both attendance and reach. “Yesterday we had about 90 students come in for the mock interviews and all of them stated that it was their first time being interviewed,” said Janeke. “Even though our office is situated on the Bloemfontein Campus, we also visit the South and Qwaqwa campuses to ensure accessibility across all three UFS campuses,” Janeke added. Emphasising results, she shared that in the 12 years she has been working in this division, student engagement has grown due to improvements in technology. 

Career Services sends out letters and emails on the 11th of each month to recognise the achievements of students who have used their services. In collaboration with the UFS’ Vision 130, more directions are being explored across the three campuses, starting with the cross-campus Shoe Camp project.

This initiative targets all UFS students, prioritising senior individuals on the cusp of job hunting. “As a postgraduate student, I am looking into getting a job next year and I have never been interviewed before, so I needed the trial run to get more information on accurate interview etiquette,” said Aphiwe Mbutuma, an Administration honours student. Mbutuma said the support she received from the staff was crucial in boosting her confidence for her next interview. She further described the experience as an eye-opener, adding that students should seize these opportunities to understand what is expected of them. Zukile Daki, a second-year student in the Faculty of Law, said: “I once bombed an interview, so I came here to improve, and it went well.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept